Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma

This study tests a new type of CAR T-cell therapy — genetically engineered immune cells that target a protein called GD2 found on neuroblastoma cells — in children with neuroblastoma whose cancer has come back or has not responded to prior treatment. **You may be eligible if...** - You are between 1 and 16 years old - You have a confirmed diagnosis of neuroblastoma - Your cancer has relapsed or is resistant to at least one prior treatment regimen - You have measurable disease that can be assessed on scans **You may NOT be eligible if...** - You are outside the 1-16 age range - Your neuroblastoma has not been previously treated - You do not have measurable disease at the time of enrollment Talk to your doctor to see if this trial is right for you.